When did COHERUS ONCOLOGY INC (CHRS) report earnings last quarter?
COHERUS ONCOLOGY INC (CHRS) last reported earnings on 3/9/2026.
COHERUS ONCOLOGY INC (CHRS) Earnings History & Surprises
NASDAQ:CHRS • US19249H1032
Current stock price
1.66 USD
-0.11 (-6.21%)
At close:
1.67 USD
+0.01 (+0.6%)
Pre-Market:
CHRS Earnings overview
Past quarterly earnings results for COHERUS ONCOLOGY INC (CHRS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.25
- Revenue Estimate
- 14.629M
Last Reported
Most Recent- Release Date
- Mar 9, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.34
- EPS Surprise
- 2.91%
- Revenue Surprise
- -10.37%
Beat Rate
Last 8 Quarters 44%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.34 | -0.35 | 2.91% | -21.43% | 12.748M | 14.223M | -10.37% | -76.46% |
| Q3 2025 | -0.33 | -0.33 | 0.45% | -3,200.00% | 11.571M | 13.681M | -15.42% | -83.65% |
| Q2 2025 | -0.34 | -0.30 | -12.36% | -142.86% | 10.254M | 10.338M | -0.81% | -84.22% |
| Q1 2025 | -0.35 | -0.24 | -47.90% | -9.37% | 7.599M | 55.753M | -86.37% | -90.14% |
| Q4 2024 | -0.28 | -0.13 | -108.91% | 54.84% | 54.144M | 48.215M | 12.30% | -40.84% |
| Q3 2024 | -0.01 | -0.14 | 92.65% | 96.30% | 70.774M | 60.415M | 17.15% | -5.09% |
| Q2 2024 | -0.14 | -0.30 | 52.67% | 63.16% | 64.979M | 62.593M | 3.81% | 10.67% |
| Q1 2024 | -0.32 | -0.25 | -29.75% | 57.33% | 77.063M | 81.853M | -5.85% | 137.58% |
| Q4 2023 | -0.62 | -0.12 | -410.06% | -3.33% | 91.524M | 98.328M | -6.92% | 101.59% |
| Q3 2023 | -0.27 | -0.28 | 3.63% | 71.88% | 74.568M | 84.363M | -11.61% | 64.25% |
| Q2 2023 | -0.38 | -0.49 | 23.14% | 19.15% | 58.716M | 54.995M | 6.77% | -2.47% |
| Q1 2023 | -0.75 | -0.58 | -28.45% | 25.00% | 32.436M | 48.386M | -32.96% | -46.03% |
| Q4 2022 | -0.60 | -0.85 | 29.82% | -30.43% | 45.4M | 52.248M | -13.11% | -38.15% |
| Q3 2022 | -0.96 | -0.58 | -65.12% | -182.35% | 45.4M | 58.048M | -21.79% | -44.97% |
| Q2 2022 | -0.47 | -0.65 | 28.05% | -30.56% | 60.2M | 63.123M | -4.63% | -31.28% |
| Q1 2022 | -1.00 | -0.49 | -103.19% | -10,100.00% | 60.1M | 70.331M | -14.55% | -27.59% |
| Q4 2021 | -0.46 | -0.52 | 11.92% | -483.33% | 73.4M | 87.526M | -16.14% | -33.51% |
| Q3 2021 | -0.34 | -0.22 | -51.52% | -203.03% | 82.5M | 93.135M | -11.42% | -27.38% |
| Q2 2021 | -0.36 | -0.15 | -135.29% | -151.43% | 87.6M | 89.943M | -2.60% | -35.45% |
| Q1 2021 | 0.01 | 0.07 | -85.70% | -98.15% | 83M | 97.923M | -15.24% | -28.57% |
| Q4 2020 | 0.12 | 0.23 | -47.83% | - | 110.4M | 117.43M | -5.99% | - |
| Q3 2020 | 0.33 | 0.41 | -20.21% | - | 113.6M | 125.34M | -9.37% | - |
| Q2 2020 | 0.70 | 0.34 | 105.06% | - | 135.7M | 107.05M | 26.76% | - |
| Q1 2020 | 0.54 | 0.57 | -4.85% | - | 116.2M | 121.91M | -4.68% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-14.22%
Max EPS beat (4)
2.91%
Min EPS beat (4)
-47.90%
Revenue beat statistics
Revenue beat (4)
0
Average Revenue beat (4)
-28.24%
Max Revenue beat (4)
-0.81%
Min Revenue beat (4)
-86.37%
Analysis
In the last 4 quarters, CHRS has beaten EPS estimates in 2 out of 4 releases
CHRS has not beaten revenue estimates in any of the last 4 earnings releases
In the last 4 quarters, CHRS reported -14.2% below the EPS estimates on average.
In the last 4 quarters, CHRS reported -28.2% below the revenue estimates on average.
Related analysis
COHERUS ONCOLOGY INC / CHRS Earnings FAQ
Did COHERUS ONCOLOGY INC (CHRS) beat earnings estimates last quarter?
COHERUS ONCOLOGY INC (CHRS) beat EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often COHERUS ONCOLOGY INC beats earnings estimates?
In the last 4 quarters, COHERUS ONCOLOGY INC (CHRS) has beaten EPS estimates in 2 out of 4 releases.